Skip to main content
Premium Trial:

Request an Annual Quote

Epigenomics, Sysmex Ink Cancer MDx Pact

NEW YORK (GenomeWeb News) – Epigenomics and Japanese firm Sysmex today said that they have entered into a research and development collaboration aimed at developing a molecular diagnostics assay for cancer based on an Epigenomics biomarker.

The companies will evaluate the suitability of Sysmex's molecular diagnostics instrumentation for detecting DNA methylation cancer biomarkers in blood. Sysmex will use Epigenomics' mSEPT9 Methylation Detection Assay as a benchmark for development of its assay. Sysmex's plan is to develop and sell in Japan a blood test for early detection of colorectal cancer based on Epigenomics' mSEPT9 biomarker.

The firms also said that they have entered into negotiations for Sysmex to take a non-exclusive license to mSEPT9.

Sysmex will have access to Epigenomics' technologies through R&D licenses and technology transfer. It also will receive R&D support from Berlin-based Epigenomics. In return, Epigenomics will receive license fees, R&D funding, and reimbursements. It also will sell its mSEPT9 research-use only assay to Sysmex.

"With Sysmex we expect to create a route to the attractive Japanese market for our early cancer detection franchise," said Epigenomics CEO Geert Nygaard in a statement.

Filed under

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.